Stock Research for ABBV

ABBV

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABBV Stock Chart & Research Data

The ABBV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABBV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABBV Due diligence Resources & Stock Charts

The ABBV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABBV Detailed Price Forecast - CNN Money CNN View ABBV Detailed Summary - Google Finance
Yahoo View ABBV Detailed Summary - Yahoo! Finance Zacks View ABBV Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABBV Trends & Analysis - Trade-Ideas Barrons View ABBV Major Holders - Barrons
NASDAQ View ABBV Call Transcripts - NASDAQ Seeking View ABBV Breaking News & Analysis - Seeking Alpha
Spotlight View ABBV Annual Report - CompanySpotlight.com OTC Report View ABBV OTC Short Report - OTCShortReport.com
TradeKing View ABBV Fundamentals - TradeKing Charts View ABBV SEC Filings - Bar Chart
WSJ View Historical Prices for ABBV - The WSJ Morningstar View Performance/Total Return for ABBV - Morningstar
MarketWatch View the Analyst Estimates for ABBV - MarketWatch CNBC View the Earnings History for ABBV - CNBC
StockMarketWatch View the ABBV Earnings - StockMarketWatch MacroAxis View ABBV Buy or Sell Recommendations - MacroAxis
Bullish View the ABBV Bullish Patterns - American Bulls Short Pains View ABBV Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABBV Stock Mentions - StockTwits PennyStocks View ABBV Stock Mentions - PennyStockTweets
Twitter View ABBV Stock Mentions - Twitter Invest Hub View ABBV Investment Forum News - Investor Hub
Yahoo View ABBV Stock Mentions - Yahoo! Message Board Seeking Alpha View ABBV Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABBV - SECform4.com Insider Cow View Insider Transactions for ABBV - Insider Cow
CNBC View ABBV Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABBV - OTC Markets
Yahoo View Insider Transactions for ABBV - Yahoo! Finance NASDAQ View Institutional Holdings for ABBV - NASDAQ


Stock Charts

FinViz View ABBV Stock Insight & Charts - FinViz.com StockCharts View ABBV Investment Charts - StockCharts.com
BarChart View ABBV Stock Overview & Charts - BarChart Trading View View ABBV User Generated Charts - Trading View




Latest Financial News for ABBV


FDA lifts hold on one of AbbVie's trials of venetoclax
Posted on Monday June 24, 2019

The U.S. Food and Drug Administration has lifted a clinical hold on one of AbbVie's Inc's trials looking at venetoclax as a potential treatment for multiple myeloma, AbbVie said Monday. The Phase 3 trial, called CANOVA, looks at venetoclax in combination with dexamethasone as a treatment for patients with advanced multiple myleoma who also have a specific genetic abnormality. The translocation abnormality, t(11;14), is one of the most commonly tested genetic abnormalities in patients with disease. AbbVie said it had agreed to revise the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria. The drugmaker can resume enrolling patients in the CANOVA trial at sites where the protocol has been approved, but all other clinical trials of venetoclax in patients with multiple myeloma are still on hold. The FDA placed a partial hold on all of AbbVie's clinical trials of venetoclax for multiple myeloma in March. The hold came after a review of another Phase 3 trial's data showed there was a higher proportion of deaths in the treatment arm than in the control arm. Shares of AbbVie have fallen 14.6% in the year to date through Friday, while the S&P 500 has gained 17.7%.


AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
Posted on Monday June 24, 2019

- FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria ...


Forget Bargain Hunting: Tap 5 Stocks With Rising P/E
Posted on Monday June 24, 2019

Bet on these top-ranked stocks with rising P/E to realize outsized gains.


Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval
Posted on Friday June 21, 2019

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.